60 related articles for article (PubMed ID: 33312454)
1. L1000 connectivity map interrogation identifies candidate drugs for repurposing as SARS-CoV-2 antiviral therapies.
Sendama W
Comput Struct Biotechnol J; 2020; 18():3947-3949. PubMed ID: 33312454
[TBL] [Abstract][Full Text] [Related]
2.
Asano T; Chelvanambi S; Decano JL; Whelan MC; Aikawa E; Aikawa M
Front Cardiovasc Med; 2022; 9():842641. PubMed ID: 35402570
[TBL] [Abstract][Full Text] [Related]
3. Host transcriptome-guided drug repurposing for COVID-19 treatment: a meta-analysis based approach.
Loganathan T; Ramachandran S; Shankaran P; Nagarajan D; Mohan S S
PeerJ; 2020; 8():e9357. PubMed ID: 32566414
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive evaluation of connectivity methods for L1000 data.
Lin K; Li L; Dai Y; Wang H; Teng S; Bao X; Lu ZJ; Wang D
Brief Bioinform; 2020 Dec; 21(6):2194-2205. PubMed ID: 31774912
[TBL] [Abstract][Full Text] [Related]
5. Systematic polypharmacology and drug repurposing via an integrated L1000-based Connectivity Map database mining.
Liu TP; Hsieh YY; Chou CJ; Yang PM
R Soc Open Sci; 2018 Nov; 5(11):181321. PubMed ID: 30564416
[TBL] [Abstract][Full Text] [Related]
6. TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19.
Ansari MA; Jamal QMS; Rehman S; Almatroudi A; Alzohairy MA; Alomary MN; Tripathi T; Alharbi AH; Adil SF; Khan M; Shaheer Malik M
Arab J Chem; 2020 Nov; 13(11):8069-8079. PubMed ID: 34909057
[TBL] [Abstract][Full Text] [Related]
7. Drug Repurposing Approach against Novel Coronavirus Disease (COVID-19) through Virtual Screening Targeting SARS-CoV-2 Main Protease.
Chowdhury KH; Chowdhury MR; Mahmud S; Tareq AM; Hanif NB; Banu N; Reza ASMA; Emran TB; Simal-Gandara J
Biology (Basel); 2020 Dec; 10(1):. PubMed ID: 33374717
[TBL] [Abstract][Full Text] [Related]
8. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
9. Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2.
Biering SB; Van Dis E; Wehri E; Yamashiro LH; Nguyenla X; Dugast-Darzacq C; Graham TGW; Stroumza JR; Golovkine GR; Roberts AW; Fines DM; Spradlin JN; Ward CC; Bajaj T; Dovala D; Schulze-Gamen U; Bajaj R; Fox DM; Ott M; Murthy N; Nomura DK; Schaletzky J; Stanley SA
ACS Infect Dis; 2021 Aug; 7(8):2337-2351. PubMed ID: 34129317
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
11. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
[TBL] [Abstract][Full Text] [Related]
12. Drug Repurposing: A Strategy for Discovering Inhibitors against Emerging Viral Infections.
Dos Santos Nascimento IJ; de Aquino TM; da Silva-Júnior EF
Curr Med Chem; 2021; 28(15):2887-2942. PubMed ID: 32787752
[TBL] [Abstract][Full Text] [Related]
13. Computational Repurposing of Drugs and Natural Products Against SARS-CoV-2 Main Protease (M
Piplani S; Singh P; Petrovsky N; Winkler DA
Front Mol Biosci; 2022; 9():781039. PubMed ID: 35359601
[TBL] [Abstract][Full Text] [Related]
14.
Gurung AB
Gene Rep; 2020 Dec; 21():100860. PubMed ID: 32875166
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns.
Mslati H; Gentile F; Perez C; Cherkasov A
J Chem Inf Model; 2021 Aug; 61(8):3771-3788. PubMed ID: 34313439
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel transmembrane Protease Serine Type 2 drug candidates for COVID-19 using computational studies.
Elbadwi FA; Khairy EA; Alsamani FO; Mahadi MA; Abdalrahman SE; Ahmed ZAM; Elsayed I; Ibraheem W; Alzain AA
Inform Med Unlocked; 2021; 26():100725. PubMed ID: 34514079
[TBL] [Abstract][Full Text] [Related]
17. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
Khan SA; Zia K; Ashraf S; Uddin R; Ul-Haq Z
J Biomol Struct Dyn; 2021 Apr; 39(7):2607-2616. PubMed ID: 32238094
[TBL] [Abstract][Full Text] [Related]
18. Graphical Learning and Causal Inference for Drug Repurposing.
Xu T; Zhao J; Xiong M
medRxiv; 2023 Aug; ():. PubMed ID: 37577650
[TBL] [Abstract][Full Text] [Related]
19. Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection.
Rao PPN; Pham AT; Shakeri A; El Shatshat A; Zhao Y; Karuturi RC; Hefny AA
Pharmaceuticals (Basel); 2021 Jan; 14(1):. PubMed ID: 33430081
[TBL] [Abstract][Full Text] [Related]
20. Potential Repurposing of Drugs with Anti-SARS-CoV-2 Activity in Preclinical Trials: A Systematic Review.
Rocha YM; de Moura GA; de Oliveira JR; de Figueiredo Nicolete LD; Nicolete R
Curr Med Chem; 2021; 28(22):4577-4585. PubMed ID: 33019921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
